Cleared Traditional

K162673 - Aptima Herpes Simplex Viruses 1 & 2 Assay (FDA 510(k) Clearance)

Jun 2017
Decision
262d
Days
Class 2
Risk

K162673 is an FDA 510(k) clearance for the Aptima Herpes Simplex Viruses 1 & 2 Assay. This device is classified as a Herpes Simplex Virus Nucleic Acid Amplification Assay (Class II - Special Controls, product code OQO).

Submitted by Hologic, Inc. (San Diego, US). The FDA issued a Cleared decision on June 15, 2017, 262 days after receiving the submission on September 26, 2016.

This device falls under the Microbiology FDA review panel. Regulated under 21 CFR 866.3305. A Polymerase Chain Reaction (pcr)-based Qualitative In Vitro Diagnostic Test For The Detection And Typing Of Herpes Simplex Virus (hsv) Dna Using Vaginal Swab Specimens..

Submission Details

510(k) Number K162673 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 26, 2016
Decision Date June 15, 2017
Days to Decision 262 days
Submission Type Traditional
Review Panel Microbiology (MI)
Summary Summary PDF

Device Classification

Product Code OQO — Herpes Simplex Virus Nucleic Acid Amplification Assay
Device Class Class II - Special Controls
CFR Regulation 21 CFR 866.3305
Definition A Polymerase Chain Reaction (pcr)-based Qualitative In Vitro Diagnostic Test For The Detection And Typing Of Herpes Simplex Virus (hsv) Dna Using Vaginal Swab Specimens.